Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RWE Study of Subjects With Wilson's Disease to Assess Clinical Utility of Measuring Copper Parameters, Including a Novel Non-ceruloplasmin Bound Copper Assay Based on Copper Protein Speciation (NCC-Sp), Standard of Care Clinical and Biochemical Assessments

NCT05783687 is registered in ClinicalTrials.gov with Orphalan as lead sponsor.

NCT NCT05783687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05783687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RWE Study of Subjects With Wilson's Disease to Assess Clinical Utility of Measuring Copper Parameters, Including a Novel Non-ceruloplasmin Bound Copper Assay Based on Copper Protein Speciation (NCC-Sp), Standard of Care Clinical and Biochemical Assessments
Lead sponsor
Orphalan
Phase
Observational
Overall status
Completed
Start date
June 28, 2023
Completion date
September 12, 2025
Enrollment
50 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

wilson disease